A new brand called Elevant has launched an NMN supplement to support cellular health
24 Mar 2021
0 Comments
Elevant (New York, NY), a brand of the Swiss biotech company Seneque, recently launched Prime capsules in the U.S. Prime is a clinically tested, high purity form of nicotinamide mononucleotide (NMN), a precursor of NAD+ (nicotinamide adenine dinucleotide). The high purity NMN, called NMN-C, is self-affirmed GRAS (generally recognized as safe) as of November 2020 after an independent panel of toxicology and nutrition experts rigorously evaluated research studies and toxicology data to conclude NMN-C was not harmful under its intended use: UL of 2.2 mg/lb for humans, or 300 mg for a 135-lb adult.
To further transparency, the results of a recent OECD 408 toxicology study on NMN-C were published. According to Elevant, this was a first of its kind study to be undertaken on NMN, analyzing the ingredient’s No Observable Adverse Effect Level (NOAEL). The company is also partnering with leading European and American institutions such as the Buck Institute for Research on Aging for preclinical research exploring the health benefits of NMN, and to propel further development of NMN-C to support cardiovascular, cognitive, muscular, skin, and immune health.
Prime is sold by Elevant directly to consumers and offers an annual subscription.
